Endovascular Engineering, a commercial-stage medical technology company focused on treating venous thromboembolism, has raised $80 million in a Series C financing round to support the commercialization of its Hēlo thrombectomy platform.
The oversubscribed round was co-led by Gilde Healthcare and Norwest, with participation from existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments, along with strategic investors. The funding will be used to scale the company’s commercial organization and continue investments in research, development, and operations.
The Hēlo thrombectomy platform is designed to treat pulmonary embolism, a leading cause of cardiovascular death. The system features a dual-action mechanism that combines aspiration with mechanical clot disruption, enabling efficient clot removal through a small-profile catheter while maintaining large-bore performance. The platform is intended to improve procedural efficiency and clinical outcomes as adoption of mechanical thrombectomy grows.
Gilde Healthcare’s participation marks a return to the venous thromboembolism category, following its prior involvement with Inari Medical. The firm expressed confidence in Endovascular Engineering’s approach and the potential for the Hēlo platform to define the next generation of thrombectomy technology.
As part of the financing, representatives from Gilde Healthcare and Norwest will join the company’s board of directors.
Endovascular Engineering continues to position itself as a key innovator in the treatment of venous thromboembolism, with a focus on improving outcomes and addressing challenges in clot removal procedures.
KEY QUOTES:
“This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the VTE space. We are incredibly proud of the capabilities of the Hēlo Platform, and this financing enables us to build a strong commercial organization while continuing important investments in R&D and Operations.”
Dan Rose, Chief Executive Officer, Endovascular Engineering
“E2 represents the type of innovation we look for – technology that meaningfully advances clinical care and has the potential to define a category. We believe the Hēlo Platform addresses unmet needs in thrombectomy and are excited to support E2 as they scale toward commercialization and broader clinical impact.”
Geoff Pardo, General Partner, Gilde Healthcare
“Pulmonary embolism is a complex and often life-threatening condition, and there remains a need for more effective procedural solutions. We are impressed by E2’s leadership team and their thoughtful approach to building a scalable commercial organization. E2’s technology will become the platform of choice for treating pulmonary embolism with mechanical thrombectomy, and we look forward to supporting their next phase of growth.”
Zack Scott, M.D., General Partner, Norwest
